Language Select


2019年 09月 16日
Varian (NYSE: VAR) has named Francis R. Facchini, M.D., FSIR, as the new chief medical officer, Interventional Oncology, reporting to Dee Khuntia, Varian chief medical officer. Effective September... Read more
2019年 09月 16日
Varian (NYSE: VAR) has been recognized again as a leader in the annual IMV ServiceTrak™ Radiation Oncology Systems report, ranking first in eight of the tracked categories. Additionally,... Read more
2019年 09月 16日
Varian (NYSE: VAR) today announced its ProBeam 360° proton therapy system is now available in a multi-room configuration. The ProBeam 360° system is the smallest multi-room system available for... Read more


2019年 09月 05日 | Centerline
Historically there has been one practical option for dealing with interfraction and intrafraction motion during stereotactic body radiotherapy (SBRT): Increase the clinical target volume. Doing so,... Read more
2019年 08月 20日 | Centerline
Varian introduced the Bravos afterloader system at ASTRO in 2018, in response to a growing need for an easy-to-use, efficient system. In this article, the clinical team at the UK-based Norfolk and... Read more
2019年 07月 08日 | Centerline
Since its introduction in 2017, Varian’s HyperArc™ high-definition radiotherapy has been deployed to deliver noncoplanar stereotactic radiosurgery (SRS) at sites around the world. Physicists in the... Read more


Corporate Communications Contact

Mark Plungy
Director, Public Relations

Investor Relations Contact

Mike Bruff
SVP, Investor Relations